<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123044</url>
  </required_header>
  <id_info>
    <org_study_id>CT 09-01</org_study_id>
    <nct_id>NCT01123044</nct_id>
  </id_info>
  <brief_title>Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease</brief_title>
  <acronym>CLET</acronym>
  <official_title>Transplantation of Cultivated Corneal Epithelial Sheet in Patients With Ocular Surface Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health, Malaysia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess if transplantation of cultivated corneal epithelial stem&#xD;
      cells could restore vision in patients with severe ocular surface disorder with a favourable&#xD;
      safety profile that warrants further comparative study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Efficacy:&#xD;
&#xD;
      To determine the efficacy of cultivated corneal epithelial stem cells as a treatment for&#xD;
      patients with severe ocular surface disorder.&#xD;
&#xD;
      The corneal limbal epithelial stem cell transplant (CLET) successful outcome will be measured&#xD;
      by improvement of vision, maintenance of corneal re-epithelisation with absence of recurrence&#xD;
      of surface disease and subjective improvement of symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of vision at one week</measure>
    <time_frame>One week</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of vision at one month</measure>
    <time_frame>One month</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of vision at three month</measure>
    <time_frame>Three month</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of vision at six month</measure>
    <time_frame>Six month</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of vision at nine month</measure>
    <time_frame>Nine month</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of vision at twelve month</measure>
    <time_frame>Twelve month</time_frame>
    <description>The primary efficacy variable will be improved visual acuity Vision will be assessed using ETDRS logMAR visual acuity measurements. An improvement of &gt; 1 line</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events reporting, vital signs, and physical examinations.</measure>
    <description>To evaluate the safety and tolerability of transplantation of limbal epithelial cells cultured on amniotic membrane for a follow-up period of one year in patients. Safety will be evaluated using adverse events reporting, vital signs, and physical examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of corneal re-epithelisation with absence of recurrence of surface disease</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective improvement of symptoms</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Eye Injury</condition>
  <arm_group>
    <arm_group_label>corneal stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conservative medical therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>conservative</intervention_name>
    <description>Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane</description>
    <arm_group_label>conservative medical therapy</arm_group_label>
    <arm_group_label>corneal stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medical Therapy</intervention_name>
    <description>Under usual care treatment</description>
    <arm_group_label>conservative medical therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non-pregnant females between 18 and 75 years of age.&#xD;
&#xD;
          2. Written informed consent obtained from patient or parents/guardian.&#xD;
&#xD;
          3. Patients with unilateral limbal stem deficiency 2-12 months presenting with any of the&#xD;
             following&#xD;
&#xD;
               -  Conjunctivalisation&#xD;
&#xD;
               -  Absence of limbal palisades of Vogts&#xD;
&#xD;
               -  Chronic inflammation&#xD;
&#xD;
               -  Persistent or recurrent corneal epithelial defect&#xD;
&#xD;
          4. Patients who had 2-12 months of conservative treatment. * Diagnostic criteria for&#xD;
             limbal stem cell deficiency are as follows:&#xD;
&#xD;
               -  Symptoms of decreased vision, redness, watering, photophobia and recurrent&#xD;
                  attacks of pain&#xD;
&#xD;
               -  Triad of signs: conjunctivalisation, neovascularisation and chronic inflammation&#xD;
&#xD;
               -  Stippled appearance of cunjunctivalised cornea with loss of palisades of Vogt&#xD;
&#xD;
               -  Recurrent and persistent epithelial defects&#xD;
&#xD;
               -  Superficial vascularisation, scarring, thick fibrovascular pannus, ulceration,&#xD;
                  melting and perforation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any of the following are not eligible for enrollment into the study:&#xD;
&#xD;
          1. Pregnant or nursing woman or women of childbearing potential except if&#xD;
             post-menopausal, surgically sterile or using accepted method(s) of birth control or&#xD;
             having negative pregnancy test.&#xD;
&#xD;
          2. Participation in any drug trial in which the patient received an investigational drug&#xD;
             within 30 days or 5 half-lives (whichever is longer) preceding the screening phase of&#xD;
             this study.&#xD;
&#xD;
          3. Those persons directly involved in the conduct of the study.&#xD;
&#xD;
          4. Any history of severe infection such as hepatitis, renal, gastrointestinal, endocrine&#xD;
             or neurological disease.&#xD;
&#xD;
          5. Evidence of corneal stromal scarring, cataract, macular oedema or scarring, retinal&#xD;
             detachment and conjunctival keratinisation&#xD;
&#xD;
          6. Positive for HIV, Hepatitis B, C and VDRL&#xD;
&#xD;
          7. History of Pulmonary tuberculosis, hepatitis B,&#xD;
&#xD;
          8. History of alcohol or substance abuse&#xD;
&#xD;
          9. History of malignancy within previous 5 years&#xD;
&#xD;
         10. History of organ transplant&#xD;
&#xD;
         11. Any serious medical conditions or disability, which in the opinion of the&#xD;
             investigator, would interfere with treatment or assessment or preclude completion of&#xD;
             this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Kuala Lumpur</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Wilayah Persekutuan</state>
        <zip>50586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <contact>
      <last_name>Umapathy</last_name>
      <email>thiagesw@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Thiages Umapathy, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>April 22, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Head Clinical Trial Unit</name_title>
    <organization>Clinical Research Centre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

